Equity
€188,097 ▲ 83.2%
Equity rose in 2025 from €102,673 to €188,097.
ALBECESA
Lifetime
8 annual accounts with figures on one time axispeak €182,946 (2024)
€172,617▼ 5.6%
lowest -€123,374 (2023)
€116,174▲ 8.2%
peak €188,097 (2025)
€188,097▲ 83.2%
€42,470▲ 407%
Board2 names since 2018
2 directors and 1 other
Documentsfilings and deeds
19-05-202673 days before the deadline
2025micro format
Dividend €30,750Equity from €102,673 to €188,097Debts from €8,380 to €42,470Cash from €87,413 to €169,735
Key points
from the 2025 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 26,973 companies had the same profile as ALBECESA has now. Each dot stands for 68 companies, two years later.
94.8%
were still trading
3.5%
stopped another way
1.6%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 26,973 companies, not a prediction for ALBECESA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, since 07-06-2018
Manager, since 07-06-2018
- all the sharesdeed of 27-02-2019
Recent changes
Reappointment: (director)
General meeting of 19-04-2023 · Gazette deed
Resignations & appointments
General meeting of 01-03-2023 · Gazette deed
Registered-office move
Gazette deed
Company renamed from Cabinet to ALBECESA
holds all the shares · General meeting of 06-02-2019 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ALBECESA Uccle | €230,568 | €172,617 | 81.6% | - |
| TOOP Leuven | €239,284 | €175,510 | 23.5% | 2.8 |
| Dr. Justine Werbrouck Kortrijk | €243,344 | €172,685 | 8.4% | - |
| LC LAB La Louvière | €276,778 | €164,808 | 52.3% | - |
| LiVFe Sint-Lievens-Houtem | €178,944 | €136,107 | 31.4% | - |
| RADI-X Esneux | €247,092 | €213,975 | 28.3% | - |
| Dokter Arne Hens Mechelen | €265,099 | €182,058 | 1.7% | - |
These companies have the same main activity as ALBECESA: medical imaging and medical laboratories (NACE 86910). They are comparable in size and age: total assets between €179,000 and €277,000, founded between 2017 and 2020.
Official details
Source: KBO- Status
- Active since 19-06-2018Normal situation
- Activity
- Medical imaging and medical laboratoriesNACE 86910
- Joint committee
- 330Health institutions and services · annual accounts 2025
- Establishment unit
- 2.277.581.8731180 Uccle, since 19-06-2018
- Financial year end
- 31 December
- Peppol
- Not found in the Peppol Directory
Annual accounts 2025
- ≈ €350,000estimated
- €230,568▲ 108%
- Employeeson 31-12-2025
- 1=
- Filing
- Filed on 19-05-2026, 73 days before the end of the filing period
Insights on ALBECESA
ALBECESA files the micro format. That format states no turnover. The gross margin rose from €45,035 in 2018 to €172,617 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ALBECESA
- What is the company number of ALBECESA?
- The company number of ALBECESA is 0698.570.838. The VAT number is the same number with BE in front: BE 0698.570.838.
- Where is ALBECESA based?
- The registered office is at Winston Churchilllaan 3, 1180 Uccle.Company details
- What does ALBECESA do?
- According to the KBO register, the main activity is medical imaging and medical laboratories (NACE 86910).
- What is the legal form of ALBECESA?
- ALBECESA is a private limited company (BV).
- When was ALBECESA founded?
- ALBECESA was founded on 19-06-2018.
- Is ALBECESA still active?
- Yes, ALBECESA is an active enterprise in the KBO register.
- How many employees does ALBECESA have?
- ALBECESA had an average of 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does ALBECESA fall under?
- In its 2025 annual accounts, ALBECESA states joint committee 330 (Health institutions and services).
- What is the turnover of ALBECESA?
- The turnover in financial year 2025 is ≈ €350,000. This figure is estimated from the gross margin of €172,617 and 81 comparable companies (NACE 86). It probably lies between €260,000 and €430,000.
- Is ALBECESA profitable?
- In financial year 2025, ALBECESA made a profit of €116,174.
- Where can I find the annual accounts of ALBECESA?
- ALBECESA filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ALBECESA due?
- ALBECESA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.